Monthly News Roundup - May 2019
Zolgensma: First Gene Therapy for Pediatric Spinal Muscular Atrophy (SMA)
Zolgensma (onasemnogene abeparvovec-xioi) from AveXis (a Novartis company), is now approved for children less than 2 years of age with spinal muscular atrophy (SMA).
SMA...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Children | Gene Therapy | Genetics | Pediatrics | Pharmaceuticals | Spinal Muscular Atrophy